Insiders Astellas Pharma Inc. OTC Markets

Equities

Delayed OTC Markets Other stock markets 09:24:58 06/06/2024 pm IST			5-day change	1st Jan Change
10.17 ^USD	-0.59%		+4.95%	-14.54%

03/06	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT
31/05	U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	CI

Astellas Pharma Inc. Announces Board and Committee Retirements	25/04	CI
Shopper360 Names Financial Controller	21/11	MT
US government names first 10 drugs for Medicare price negotiation	29/23/29	RE
US to name first 10 drugs for Medicare price negotiation	29/23/29	RE
INTERVIEW - Naoki Okamura, CEO of Astellas Pharma: business strategy and healthcare outlook	17/23/17	MT
Astellas Pharma Rejigs Top Management	07/23/07	MT
Astellas Pharma Inc. Announces Executive Changes	06/23/06	CI
Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023	06/23/06	CI
Astellas Pharma Inc. Appoints Steve Sabus as Chief Commercial Officer	05/22/05	CI
Syndax Pharmaceuticals Names Steve Sabus Chief Commercial Officer	02/22/02	MT
Astellas Pharma Inc. Announces Executive Changes	02/22/02	CI
Astellas Pharma Inc. Announces Keiko Yamagami to Resign as Director	27/21/27	CI
Astellas Announces Executive Changes	04/21/04	CI
Astellas Establishes Global Patient Centricity Leadership Structure	23/20/23	CI
Astellas Pharma : Named to FTSE4Good Index Series for Ninth Consecutive Year	20/20/20	AQ
Astellas Pharma Inc. Announces Directorate and Committee Resignations	27/20/27	CI
Astellas Appoints David Fryrear as New Global Head of Clinical and Research Quality Assurance Organization	06/19/06	CI
Astellas Pharma : Named to FTSE4Good Index Series for the Eighth Consecutive Year	26/19/26	PU
Astellas Pharma Inc. Announces Executive Promotions	03/19/03	CI
Astellas Pharma Inc. Announces Executive Promotions and New Hire in Legal, IP and Immuno-Oncology	01/19/01	CI

No results for this search